MedTrace Logo

Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis

NCT01512277 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-08-27

No results posted yet for this study

Summary

The purpose of this clinical study is to evaluate safety and immunogenicity in adult healthy volunteers of the vaccine candidate against schistosomiasis named Bilhvax.

Conditions

  • Schistosomiasis
  • Bilharziasis
  • Urinary Schistosomiasis

Interventions

BIOLOGICAL

rSh28GST

subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • André CAPRON, MD · Institut National de la Santé Et de la Recherche Médicale, France

  • Gilles RIVEAU, PhD · Institut National de la Santé Et de la Recherche Médicale, France

  • Christian LIBERSA, MD · CIC, University Hospital, Lille

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-09-30
Primary Completion
1999-03-31
Completion
1999-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01512277 on ClinicalTrials.gov